



Received for publication, October, 2, 2018

Accepted, December, 3, 2018

Original paper

Effects of silver nanoparticles on nosocomial *Pseudomonas aeruginosa* strains – an alternative approach for antimicrobial therapy

SUMAYAH ABDULHUSSIEN IBRAHEEM¹, HAITHAM ALI KADHEM, SARMED AL HADEETHI, MAJID SAKHI JABIR², RALUCA GRIGORE³, MARCELA POPA^{4,5}, IRINA GHEORGHE^{4,5}, MIHAILESCU DAN FLORIN¹

¹Department of Animal Physiology and Biophysics, Faculty of Biology, Bucharest, Romania

²Department of Applied science/University of Technology/Baghdad/Iraq

³Carol Davila University of Medicine and Pharmacy,

³University of Bucharest, Faculty of Biology, Department of Microbiology

⁴Research Institute of the University of Bucharest

Abstract

Nanotechnology is emerging as a new interdisciplinary field combining microbiology, chemistry, physics, and material science. Nanoparticles (NPs) act as excellent antimicrobial agents with potential clinical applications. Silver NPs (AgNPs) have been successfully used in a wide range of applications including wound dressing, protective clothing, antibacterial surfaces, food preservation, and cosmetics as biocide and disinfecting agents. The aim of the study was the evaluation of the antimicrobial activities of AgNPs against *Pseudomonas (P.) aeruginosa* clinical isolates, identification of the morphological changes of *P. aeruginosa* cells after treatment with AgNPs by scanning electron microscopy (SEM), and the impact of the AgNPs on the viability and virulence (azurin gene expression) of *P. aeruginosa* isolates.

Keywords Silver nanoparticles, antimicrobial activity, *Pseudomonas aeruginosa*, Azurin gene

To cite this article: IBRAHEEM SA, KADHEM HA, HADEETHI SA, JABIR MS, GRIGORE R, POPA M, GHEORGHE I, MD. Effects of silver nanoparticles on nosocomial *Pseudomonas aeruginosa* strains – an alternative approach for antimicrobial therapy. *Rom Biotechnol Lett.* 2019; 24(2): 286-293. DOI: 10.25083/rbl/24.2/286.293

✉ *Corresponding author: IRINA GHEORGHE, University of Bucharest, Faculty of Biology, Department of Microbiology; Research Institute of the University of Bucharest
E-mail: IRYNA_84@yahoo.com

Introduction

The term nanotechnology is widely employed in various fields like engineering, medicine, biology, and electronics. Nanoparticles (NPs) are fine structures with size composition within the range of nanometer scale (Godasu, [1]). Nanotechnology plays a central role in the recent technological advances in the areas of the disease diagnosis, drug design and delivery. The nano technological applications for disease treatment, diagnosis, monitoring, and for the control of biological systems are referred to as nanomedicine (Moghimani & al., [2]; Vamanu & al., [3]). In nanotechnology, NPs provide several solutions to the technological and climate challenges in the areas of solar energy transformation, catalysis and medicine. Silver NPs (AgNPs) harbor many advantages due to their bacteriostatic and bactericidal activity against many pathogens. Currently, AgNPs are typically applied to antibacterial/antifungal products in biotechnology and are also used in bioengineering, textile engineering, drinking water treatment, silver-based consumer products or services. Their applications were recently extended to household products and solutions including electronic devices such as vacuum cleaners, the air cleaners, purifiers, room or space sanitizers and also water purification units. Due to their potent anti-bacterial activities, AgNPs are employed in numerous textiles but as well as coatings on certain implants. Further, AgNPs are used for the treatment of injuries and also burns or contraceptives (Wijnhoven & al., [4]). Their physical properties, particularly their size, shape and surface area are particularly important to identify their mechanisms of interaction. It is known that small materials have a larger surface area and therefore, get a greater probability to be toxic (Johnston & al., [5]; Rycenga & al., [6]). The interaction between nanoparticles and bacterial surfaces cause changes in the membrane properties. The small size and large surface area of AgNPs lead to adhesion on the bacterial surface and to a better antimicrobial activity (Wei & al., [7]; Antony & al., [8]; Reidy & al., [9]).

Pseudomonas (P.) aeruginosa is a Gram negative nonfermenting opportunistic bacterium found in water, moist environments (Staradumskyt & al. [10])) and hospital settings, exhibiting resistance to numerous classes of antibiotics (multidrug resistance) like β -lactams (penicillins, carbapenems), aminoglycosides, quinolones and ciprofloxacin (Merezeanu & al., [11]) (Moore & Flaws, [12]; Lyczak & al., [13]). Azurin is a small, blue, copper-containing protein involved in electron transport during respiration of several microorganisms. Azurin is a 128-amino-acid periplasmic protein produced by the *P. aeruginosa* with antimicrobial activity (Amdursky & al., [14]).

The aim of the study was the characterization of AgNPs in terms of their effectiveness on *P. aeruginosa*

isolates and also the investigation of the antimicrobial mechanism action of AgNPs.

Material and methods

1. Bacterial isolates

Forty *P. aeruginosa* strains were isolated from patients with different infections (data not shown). The strain isolation was made on MacConkey Agar, CLED Agar and Cetrimide Agar medium. The identification of the isolates was performed using the VITEK II automatic analyzer (BioMerieux). The *P. aeruginosa* ATCC 27853 were used as reference strain (Atlas & al. [15])

2. Characterizations of AgNPs

2.1. Scanning microscopy technique (SEM)

SEM was used to identify the morphological changes of AgNPs. AgNPs were centrifuged at 6000 r.p.m, for 5 minutes, washed 3 times with PBS (50mM, pH=7.3). From that point forward, a thin smear of the suspensions was spread on a silicon wafer slide and dried at room temperature; subsequently the silicon wafer slides were fixed with 1 ml of fixing buffer (sodium cacodylate with 2.5 wt% glutaraldehyde and 0.1M sucrose) and incubated at 37°C for 1.5 h. The fixed samples on SEM stubs were sputtered with a 20 nm gold layer (for 5 min) to permit SEM perception (Kockro & al., [16]).

2.2. Atomic Force Microscope (AFM)

AgNPs were air-dried and their size, morphology and Ag clustering were visualized by AFM (Model-Nanosurf easyscan 2 AFM, Switzerland). AFM images were taken with silicon cantilevers with a force constant 0.02–0.77 N/m, tip height 10–15 nm (Logeswari & al., [17]). De-ionized water was used as blank.

2.3. The AgNPs activity on *P. aeruginosa*

2.3.1. Antimicrobial activity of AgNPs

Antimicrobial activity of AgNPs against *P. aeruginosa* strains was analyzed on Mueller Hinton (MH) agar plates using a disk diffusion method. Fresh bacterial strains were adjusted to a density corresponding to 0.5 McFarland (Saviuc & al., [18]). For this purpose, 5 μ L from a stock solution of the tested product, containing different concentrations of NPs (25, 50, 75, and 100 μ g/ml), as well as the control used at the same concentration, were distributed on a blank paper disk. Dimethyl sulfoxide (DMSO) was used as solvent and comparatively tested for its potential antimicrobial activity. All the experiments were performed in triplicate. The plates were incubated for 24h at 37°C. The antimicrobial activity was quantified by measuring the bacterial growth inhibition zones around the spots.

The antimicrobial activity of AgNPs was evaluated also by fluorescent microscopy. The bacterial strains were cultured at 37°C for 24h on MH agar plates. One bacterial

colony was used to inoculate 10 ml of nutrient broth medium then the tubes were incubated for 24h at 37°C. After incubation 1ml of *P. aeruginosa* was added to 50 ml of nutrient broth culture media with Silver nanoparticles at concentration 50µg/ml then incubated at 37°C for another 24hr with shaking. The bacterial growth was estimated by reading optical density at 600nm using spectrophotometer.

In order to detect the impact of the AgNPs on the viability of *P. aeruginosa* cells were stained with Acridine orange / Ethidium Bromide (AO/EtBr). For this, 20 µl of bacterial suspension and 5 µl of AO/EtBr were incubated for 10 minutes and then the sample were centrifuged 15 min at 1500 r.p.m and washed with PBS three times. After that 5 µl of each sample were plated on a slide and were analyzed by fluorescence microscopy (Jabir & et al., [19]).

2.3.2. Effect of AgNPs on expression of azurin gene

Quantitative Real-Time PCR (RT-PCR) was used to evaluate the effect of AgNPs on *P. aeruginosa* azurin gene expression. The primers used for amplification of azurin gene were F:5'-ATGCTACGTAAACTCGCTG-3', R:5'-CACTTCAGGGTCAGGGTG-3'. RNA was extracted from *P. aeruginosa* using a commercial purification system (Abcam ExCellenCT Lysis Kit). The concentration of RNA had been between (40 and 50) ng/µl. The 16s rRNA gene

was used as housekeeping gene. Detection of gene expression have been performed using Abm's One-Step BrightGreen qRT-PCR Kit (Dumas & al., [20]).

2.3.3. Statistical analysis

The obtained data were statically analyzed using unpaired T-test with GraphPad Prism 6. The values were presented as the Mean ± S.E of the three replicate of each experiments.

Results and Conclusion

1. Characterization of AgNPs by SEM

The SEM images revealed that the investigated nanoparticles had spherical shape and the average size diameter of AgNPs ranged between 20-30 nm. AgNPs have uniform distribution (fig. 1A).

2. Characterization of AgNPs by AFM

AFM showed the topo-graphic image of well-dispersed AgNPs (fig. 1B) and revealed the formation of spherical AgNPs. The AFM image showed the Ag nanoparticles as crystals on a nanometer scale.

3. Morphological analysis




Figure 1. Morphological analysis (A-SEM, B-AFM) for AgNPs

Antimicrobial activity of AgNPs

Cell impermeability is particularly important for the antimicrobial resistance mechanisms in bacteria. The cell wall structure of Gram negative bacteria, and particularly the presence of an outer membrane, is often responsible for the impermeability of antimicrobial agents, (Escárcega-González & al., [21]). Consequently, the use of AgNPs should increase drug susceptibility of bacterial strains by inducing changes in the permeability of the cell membrane (Moore & Flaws, [12]; Kim & al., [22]).

The results concerning the antimicrobial activity of AgNPs against *P. aeruginosa* isolates are shown in fig. 2.

The susceptibility of the *P. aeruginosa* increases with concentration of AgNPs. At 25 µg/ml concentration AgNPs produces an inhibition area with 13 mm in diameter while at 50 µg/ml the inhibition zone was 20 mm. The largest inhibition zone was 32 mm at 100 µg/ml (fig. 2).

Based on obtained results we can confirm the role of AgNPs in inhibiting the growth of *P. aeruginosa* strains and we can suggest that AgNPs can represent a new generation of antimicrobial compounds which could be effective against multidrug resistant microorganisms.

4. Bacterial morphology after exposure to AgNPs

Interaction of bacterial cell with AgNPs can lead to cell membrane damage (Ivask & al., [23]). SEM analysis revealed the differences between the bacterial cells treated with AgNPs and non-treated bacterial cells. The bacterial cells that have not been exposed to AgNPs were bacillus-shaped, with an intact cell surface, while the bacterial cells treated with AgNPs at concentration 50µg/ml underwent considerable structural changes (fig. 3).

Previous studies have shown that exposure of bacterial strains to AgNPs can produce structural changes in outer cell membrane leading to cell death (Sondi & Salopek-Sondi, [24]; Ramalingam & al., [25]). AgNPs cause cells damage by their ability to bind cell surface proteins and lipopolysaccharides. The disorganization of cell membrane leads to an increased osmotic imbalance produced by leakage outside the cell (Cohen, [26]).




Figure 2. Antimicrobial activity of AgNPs against *P. aeruginosa*. 0- negative control, 1- AgNPs concentration 25µg/ml, 2- AgNPs concentration 50µg/ml, 3- AgNPs concentration 75µg/ml, 4- AgNPs concentration 100µg/ml. The values are shown as the mean ± SD *p<0.05, **p<0.01, ***p<0.001.




Figure 3. The effect of AgNPs on *P. aeruginosa* morphology, viability and virulence. **A.** Visualization of *P. aeruginosa* treated with Silver nanoparticles using SEM, treated bacterial cells showing membrane damage. **B.** Fluorescence microscopic images of the green / red fluorescence stained *P. aeruginosa* in the absence / presence of AgNPs. **C.** Influence of AgNPs on azurin gene expression. The value is shown as the mean±SD.

5. AO/EtBr dual staining

The impact of tested AgNPs on the viability of *P. aeruginosa* isolates was investigated using fluorescent microscopy after AO/EtBr staining. After interaction with AgNPs, most bacterial cells lose their membrane integrity and are stained with ethidium bromide (shown in red, Figure 4).

DNA damages caused by NPs may be occur by several distinct mechanisms. NPs cause direct chemical damage to DNA, by binding and inducing double-strand breaks (Singh & al., [27]). There are studies reporting that some NPs interact with proteins which inhibit the ligase domain of topoisomerase enzymes, leaving the nuclease domains intact and thereby permitting the enzyme to cut DNA without re-ligation (Pizarro-Cerdá & Cossart, [28]). A commonly observed example of this is the production of reactive oxygen species (ROS) in response to manufacturing compounds and the incorporation of oxidized guanine residues into the genome (Vizcarra & al., [29]). The results from this study suggest that the effect on membrane proteins and the oxidative stress induced by AgNPs are the main mechanism responsible for the antimicrobial activity (Zhang & al., [30]). This study proposes possible mechanisms underlying AgNPs induced cytotoxicity for the bacterial cells. First, AgNPs induce oxidative stress, leading to cell membrane instability and increased membrane permeability by incorporation of AgNPs and forming permeable pits on the membrane, which leads to an osmotic collapse in the cells and a release of the intracellular materials.

6. Effect of AgNPs on expression of azurin gene

The influence of AgNPs on azurin gene expression was evaluated through RT-PCR, using 16s rRNA gene as a housekeeping gene. As shown in fig. 5, the presence of AgNPs induce downregulation of azurin gene in *P. aeruginosa* strain comparing with non-treated cells (mean±SD 0.9800±0.09074) and treated (mean±SD 0.4100±0.04583).

Previous studies have indicated that azurin produced by *P. aeruginosa* strains function as an electron donor of the nitrite oxidase. A location of this enzyme on the periplasmic side of the plasma membrane or in the outer membrane would produce the requirement for the azurin to be present in the periplasmic space (Canters, [31]). Azurin is a redox protein initially believed only to serve as an electron donor to nitrite reductase during anaerobic respiration (Cutruzzolà & al., [32]). However, the periplasmic azurin of *P. aeruginosa* is not essential for denitrification, but is involved in protection from oxidative stress (Wu & al., [33]; Tomkinson, [34]). There are some studies which confirm that azurin represents a virulence factor of *P. aeruginosa* strains due to their cytotoxicity against phagocytic cells (Goto & al., [35]; Zaborina & al., [36]).

The results obtained within this study highlight that AgNPs are remarkably well effective in inhibiting growth

of bacterial isolates. These results confirmed that the bactericidal effect of AgNPs can be translated into important therapeutic and clinical options in the future, especially considering the shortage of new antimicrobials agents against the emerging multidrug resistant microorganisms, therefore AgNPs may act as a powerful tool against multidrug-resistant bacteria. AgNPs were also associated with attenuation of the virulence by inducing a decrease in expression of the gene coding for azurin in the *P. aeruginosa* strains.

Acknowledgments

The financial support of the research projects PN-III-P1.1-PD-2016-1798 (PD 148/2018), PNIII-P4-ID-PCE-2016-0884, within PNCDI III. and PNIII-P4-ID-PCCF-2016-0114, granted by the Executive Unit for Financing Higher Education, Research, Development and Innovation (UEFISCDI) are gratefully acknowledged.

References

- Godasu R. Synthesis and characterization of nano Cdo/NiO, nano Ag/ZnO composites & Ag/Zno embedded polymer nanocomposites. Long Island University, The Brooklyn Center. 55-04, (2016).
- Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. *The FASEB Journal*, 19(3): 311-330, (2005).
- Vamanu E, Ene M, Bitu B, Ionescu C, Craciun L, Sarbu I. In vitro human microbiota response to exposure to silver nanoparticles biosynthesized with mushroom extract. *Nutrients*, 10: 607, (2018).
- Wijnhoven SW, Peijnenburg WJ, Herberts CA, Hagens WI, Oomen AG, Heugens EH, Van De Meent, D. Nano-silver—a review of available data and knowledge gaps in human and environmental risk assessment. *Nanotoxicology*, 3(2): 109-138, (2009).
- Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V. A review of the *in vivo* and *in vitro* toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. *Crit Rev Toxicol*. 40(4):328-46, (2010).
- Rycenga M, Cogley CM, Zeng J, Li W, Moran CH, Zhang Q, Xia Y. Controlling the synthesis and assembly of silver nanostructures for plasmonic applications. *Chemical reviews*, 111(6): 3669-3712, (2011).
- Wei L, Lu J, Xu H, Patel A, Chen ZS, Chen G. Silver nanoparticles: synthesis, properties, and therapeutic applications. *Drug discovery today*, 20(5): 595-601, (2015).
- Antony JJ, Sivalingam P, Siva D, Kamalakkannan S, Anbarasu K, Sukirtha R, Achiraman S. Comparative evaluation of antibacterial activity of silver nanoparticles

- synthesized using *Rhizophora apiculata* and glucose. *Colloids and Surfaces B: Biointerfaces*, 88(1): 134-140, (2011).
9. Reidy B, Haase A, Luch A, Dawson KA, Lynch I. Mechanisms of silver nanoparticle release, transformation and toxicity: a critical review of current knowledge and recommendations for future studies and applications. *Materials*, 6(6): 2295-2350, (2013).
 10. Daiva Staradumskyte, Algimantas Paulauskas. Non-Fermentative Gram-Negative Bacteria in Drinking Water. *Journal of Water Resource and Protection*, 6: 114-119,(2014).
 11. Merezeanu N, Gheorghe I, Popa M, Chifiriuc MC, Pântea O, Lazăr V, Banu O, Bolocan A, Grigore R, Bertșteanu SV. Virulence and resistance features of *Pseudomonas aeruginosa* strains isolated from patients with cardiovascular diseases. *Biointerface Res. Appl. Chem.* 6 (2):1117-1121, (2016).
 12. Moore NM, Flaws ML. Antimicrobial resistance mechanisms in *Pseudomonas aeruginosa*. *Clinical Laboratory Science*, 24(1): 47, (2011).
 13. Ivask A, Rõlova T, Kahru A. A suite of recombinant luminescent bacterial strains for the quantification of bioavailable heavy metals and toxicity testing. *BMC biotechnology*, 9(1), 41, (2009).
 14. Amdursky N, Pecht I, Sheves M, Cahen D. Marked changes in electron transport through the blue copper protein azurin in the solid state upon deuteration. *Proceeding of the National Academy of Sciences*, 110 (2): 507-512, (2013).
 15. Atlas RM, Brown AE, Parks LC. (1995). *Laboratory manual of experimental microbiology*: Mosby. (1995).
 16. Kockro RA, Hampl JA, Jansen B, Peters G, Scheihing M, Giacomelli R et al. (2000). Use of scanning electron microscopy to investigate the prophylactic efficacy of rifampin-impregnated CSF shunt catheters. *Journal of medical microbiology*, 49(5): 441-450, (2000).
 17. Logeswari P, Silambarasan S, Abraham J. Synthesis of silver nanoparticles using plants extract and analysis of their antimicrobial property. *Journal of Saudi Chemical Society*, 19(3): 311-317, (2015).
 18. Saviuc C, Grumezescu AM, Holban A, Bleotu C, Chifiriuc C, Balaure P, Lazar V. Phenotypical studies of raw and nanosystem embedded *Eugenia carryophyllata* buds essential oil antibacterial activity on *Pseudomonas aeruginosa* and *Staphylococcus aureus* strains. *Biointerface Res. Appl. Chem.*, 1(3):111-118, (2011).
 19. Jabir MS, Sulaiman GM, Taqi ZJ, Li D. Iraqi propolis increases degradation of IL-1 β and NLR4 by autophagy following *Pseudomonas aeruginosa* infection. *Microbes and infection*, 20(2), 89-100, (2018).
 20. Dumas JL, van Delden C, Perron K, Köhler T. Analysis of antibiotic resistance gene expression in *Pseudomonas aeruginosa* by quantitative real-time-PCR. *FEMS Microbiology Letters*, 254(2), 217-225, (2006).
 21. Escárcega-González CE, Garza-Cervantes J, Vázquez-Rodríguez A, Montelongo-Peralta LZ, Treviño-González M, Castro EDB, et al. In vivo antimicrobial activity of silver nanoparticles produced via a green chemistry synthesis using *Acacia rigidula* as a reducing and capping agent. *International Journal of Nanomedicine*, 13, 2349-2363, (2018).
 22. Kim SH, Lee HS, Ryu DS, Choi SJ, Lee DS. Antibacterial activity of silver-nanoparticles against *Staphylococcus aureus* and *Escherichia coli*. *Korean J. Microbiol. Biotechnol*, 39(1): 77-85, (2011).
 23. Ivask A, Rõlova T, Kahru A. A suite of recombinant luminescent bacterial strains for the quantification of bioavailable heavy metals and toxicity testing. *BMC biotechnology*, 9(1), 41, (2009).
 24. Sondi I, Salopek-Sondi, B. Silver nanoparticles as antimicrobial agent: a case study on *E. coli* as a model for Gram-negative bacteria. *Journal of Colloid and Interface Science*, 275(1): 177-182, (2004).
 25. RAMALINGAM BASKARAN, PARANDHAMAN THANUSU, DAS SUJOY K. Antibacterial effects of biosynthesized silver nanoparticles on surface ultrastructure and nonmechanical properties of gram-negative bacteria viz. *Escherichia coli* and *Pseudomonas aeruginosa*. *ACS applied materials & interfaces*, 8(7): 4963-4976, (2016).
 26. Cohen BE. (2014). Functional linkage between genes that regulate osmotic stress responses and multidrug resistance transporters: challenges and opportunities for antibiotic discovery. *Antimicrobial Agents and Chemotherapy*, 58(2): 640-646, (2014).
 27. Singh R, Smitha MS, Singh SP. The role of nanotechnology in combating multi-drug resistant bacteria. *J Nanosci Nanotechnol*. 14(7):4745-56, (2014).
 28. Pizarro-Cerdá J, Cossart P. Bacterial adhesion and entry into host cells. *Cell*. 124(4):715-27, (2006).
 29. Vizcarra GO, Casagrande M, Nimbalkar SS. Modeling Behaviour of Railway Ballast in Prismoidal Apparatus Using Discrete Element Method. 143:1177-1184, (2016).
 30. Zhang D, Gökce B, Barcikowski S. Laser Synthesis and Processing of Colloids: Fundamentals and Applications. *Chem Rev*. 8;117(5):3990-4103, (2017).
 31. Canters G. The azurin gene from *Pseudomonas aeruginosa* codes for a pre-protein with a signal peptide: Cloning and sequencing of the azurin gene. *FEBS letters*, 212(1): 168-172, (1987).
 32. Cutruzzolà F, Arese M, Ranghino G, van Pouderoyen G, Canters G, Brunori M. *Pseudomonas aeruginosa* cytochrome C551: probing the role of the hydrophobic patch in electron transfer. *Journal of Inorganic Biochemistry*, 88(3): 353-361, (2002).
 33. Wu HJ, Seib KL, Edwards JL, Apicella MA, McEwan AG, Jennings MP. Azurin of Pathogenic *Neisseria* spp. Is Involved in Defense against Hydrogen Peroxide and Survival within Cervical Epithelial Cells. *Infection and Immunity*, 73(12): 8444-8448, (2005).
 34. Tomkinson K. (2013). *Triplasma Copper Homeostasis in Pseudomonas aeruginosa*. Worcester Polytechnic Institute. <https://web.wpi.edu/Pubs/E-project/Available/>

- E-project-030113-233033/unrestricted/Kaleigh_Tomkinson_MQP.pdf.
35. Goto M, Yamada T, Kimbara K, Horner J, Newcomb M, Gupta TD, Chakrabarty A. Induction of apoptosis in macrophages by *Pseudomonas aeruginosa* azurin: tumour-suppressor protein p53 and reactive oxygen species, but not redox activity, as critical elements in cytotoxicity. *Molecular microbiology*, 47(2): 549-559, (2003).
 36. Zaborina O, Dhiman N, Chen ML, Kostal J, Holder IA, Chakrabarty AM. Secreted products of a nonmucoid *Pseudomonas aeruginosa* strain induce two modes of macrophage killing: external-ATP-dependent, P2Z-receptor-mediated necrosis and ATP-independent, caspase-mediated apoptosis. *Microbiology*, 146(10): 2521-2530, (2000).
 37. Ivask A, Rõlova T, Kahru A. A suite of recombinant luminescent bacterial strains for the quantification of bioavailable heavy metals and toxicity testing. *BMC biotechnology*, 9(1), 41, (2009).
 38. Merezeanu N, Gheorghe I, Popa M, Chifiriuc MC, Pântea O, Lazăr V, Banu O, Bolocan A, Grigore R, Berteșteanu SV. Virulence and resistance features of *Pseudomonas aeruginosa* strains isolated from patients with cardiovascular diseases. *Biointerface Res. Appl. Chem.* 6 (2):1117-1121, (2016).
 39. Najm WA, Bolocan A, Ionescu D, Ionescu B, Gheorghe I, Banu O, Mihăilescu D, Decuseara A. Etiology and resistance patterns of *Pseudomonas aeruginosa* strains isolated from a Roumanian hospital. *Biointerface Res. Appl. Chem.* 5 (5): 986-991, (2015).
 40. Saviuc C, Grumezescu AM, Holban A, Bleotu C, Chifiriuc C, Balaure P, Lazăr V. Phenotypical studies of raw and nanosystem embedded *Eugenia carryophyllata* buds essential oil antibacterial activity on *Pseudomonas aeruginosa* and *Staphylococcus aureus* strains. *Biointerface Res. Appl. Chem.*, 1(3):111-118, (2011).
 41. Jabir MS, Sulaiman GM, Taqi ZJ, Li D. Iraqi propolis increases degradation of IL-1 β and NLRC4 by autophagy following *Pseudomonas aeruginosa* infection. *Microbes and infection*, 20(2), 89-100, (2018)a.
 42. Jabir MS, Taha AA, Sahib UI. Linalool loaded on glutathione-modified gold nanoparticles: a drug delivery system for a successful antimicrobial therapy. *Artificial Cells, Nanomedicine, and Biotechnology*, 4: 1-11.(2018)b .
 43. Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V. A review of the *in vivo* and *in vitro* toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. *Crit Rev Toxicol.* 40(4):328-46, (2010).
 44. Pal SL, Jana U, Manna PK, Mohanta GP, Manavalan R. Nanoparticle: an overview of preparation and characterization. *Journal of Applied Pharmaceutical Science*, 1(6): 228-234, (2011).
 45. Kim SH, Lee HS, Ryu DS, Choi SJ, Lee DS. Antibacterial activity of silver-nanoparticles against *Staphylococcus aureus* and *Escherichia coli*. *Korean J. Microbiol. Biotechnol.*, 39(1): 77-85, (2011).
 46. Kockro RA, Hampl JA, Jansen B, Peters G, Scheihing M, Giacomelli R *et al.* (2000). Use of scanning electron microscopy to investigate the prophylactic efficacy of rifampin-impregnated CSF shunt catheters. *Journal of medical microbiology*, 49(5): 441-450, (2000).
 47. Logeswari P, Silambarasan S, Abraham J. Synthesis of silver nanoparticles using plants extract and analysis of their antimicrobial property. *Journal of Saudi Chemical Society*, 19(3): 311-317, (2015).
 48. Lyczak JB, Cannon CL, Pier GB. Establishment of *Pseudomonas aeruginosa* infection: lessons from a versatile opportunist. *Microbes and infection*, 2(9): 1051-1060, (2000).
 49. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. *The FASEB Journal*, 19(3): 311-330, (2005).
 50. Moore NM, Flaws ML. Antimicrobial resistance mechanisms in *Pseudomonas aeruginosa*. *Clinical Laboratory Science*, 24(1): 47, (2011).
 51. Ramalingam B, Parandhaman T, Das SK. Antibacterial effects of biosynthesized silver nanoparticles on surface ultrastructure and nanomechanical properties of gram-negative bacteria viz. *Escherichia coli* and *Pseudomonas aeruginosa*. *ACS applied materials & interfaces*, 8(7): 4963-4976, (2016).
 52. Rao A, Schoenenberger M, Gnecco E, Glatzel T, Meyer E, Brändlin D, Scandella L. Characterization of nanoparticles using atomic force microscopy. *Paper presented at the Journal of Physics*, 61(1): 971-976 (2007).
 53. Reidy B, Haase A, Luch A, Dawson KA, Lynch I. Mechanisms of silver nanoparticle release, transformation and toxicity: a critical review of current knowledge and recommendations for future studies and applications. *Materials*, 6(6): 2295-2350, (2013).
 54. Rycenga M, Cobley CM, Zeng J, Li W, Moran CH, Zhang Q, Xia Y. Controlling the synthesis and assembly of silver nanostructures for plasmonic applications. *Chemical reviews*, 111(6): 3669-3712, (2011).
 55. Vamanu E, Ene M, Bită B, Ionescu C, Crăciun L, Sarbu I. *In vitro* human microbiota response to exposure to silver nanoparticles biosynthesized with mushroom extract. *Nutrients*, 10: 607, (2018).
 56. Sondi I, Salopek-Sondi, B. Silver nanoparticles as antimicrobial agent: a case study on *E. coli* as a model for Gram-negative bacteria. *Journal of Colloid and Interface Science*, 275(1): 177-182, (2004).
 57. Tomkinson K. (2013). Periplasmic Copper Homeostasis in *Pseudomonas aeruginosa*. Worcester Polytechnic Institute. https://web.wpi.edu/Pubs/E-project/Available/E-project-030113-233033/unrestricted/Kaleigh_Tomkinson_MQP.pdf.

58. Wang JX, Wen LX, Wang ZH, Chen JF. Immobilization of silver on hollow silica nanospheres and nanotubes and their antibacterial effects. *Materials chemistry and Physics*, 96(1): 90-97, (2006).
59. Wei L, Lu J, Xu H, Patel A, Chen ZS, Chen G. Silver nanoparticles: synthesis, properties, and therapeutic applications. *Drug discovery today*, 20(5): 595-601, (2015).
60. Wijnhoven SW, Peijnenburg WJ, Herberts CA, Hagens WI, Oomen AG, Heugens EH, Van De Meent, D. Nano-silver—a review of available data and knowledge gaps in human and environmental risk assessment. *Nanotoxicology*, 3(2): 109-138, (2009).
61. Wu HJ, Seib KL, Edwards JL, Apicella MA, McEwan AG, Jennings MP. Azurin of Pathogenic *Neisseria* spp. Is Involved in Defense against Hydrogen Peroxide and Survival within Cervical Epithelial Cells. *Infection and Immunity*, 73(12): 8444-8448, (2005).
62. Zaborina O, Dhiman N, Chen ML, Kostal J, Holder IA, Chakrabarty AM. Secreted products of a nonmucoid *Pseudomonas aeruginosa* strain induce two modes of macrophage killing: external-ATP-dependent, P2Z-receptor-mediated necrosis and ATP-independent, caspase-mediated apoptosis. *Microbiology*, 146(10): 2521-2530, (2000).
63. Canters G. The azurin gene from *Pseudomonas aeruginosa* codes for a pre-protein with a signal peptide: Cloning and sequencing of the azurin gene. *FEBS letters*, 212(1): 168-172, (1987).
64. Cohen BE. Functional linkage between genes that regulate osmotic stress responses and multidrug resistance transporters: challenges and opportunities for antibiotic discovery. *Antimicrobial Agents and Chemotherapy*, 58(2): 640-646, (2014).
65. Cutruzzolà F, Arese M, Ranghino G, van Pouderoyen G, Canters G, Brunori M. *Pseudomonas aeruginosa* cytochrome C551: probing the role of the hydrophobic patch in electron transfer. *Journal of Inorganic Biochemistry*, 88(3): 353-361, (2002).
66. Goto M, Yamada T, Kimbara K, Horner J, Newcomb M, Gupta TD, Chakrabarty A. Induction of apoptosis in macrophages by *Pseudomonas aeruginosa* azurin: tumour-suppressor protein p53 and reactive oxygen species, but not redox activity, as critical elements in cytotoxicity. *Molecular microbiology*, 47(2): 549-559, (2003).
67. Singh R, Smitha MS, Singh SP. The role of nanotechnology in combating multi-drug resistant bacteria. *J Nanosci Nanotechnol*. 14(7):4745-56, (2014).
68. Pizarro-Cerdá J, Cossart P. Bacterial adhesion and entry into host cells. *Cell*. 124(4):715-27, (2006).
69. Vizcarra GO, Casagrande M, Nimbalkar SS. Modeling Behaviour of Railway Ballast in Prismatic Apparatus Using Discrete Element Method. 143:1177-1184, (2016).
70. Zhang D, Gökce B, Barcikowski S. Laser Synthesis and Processing of Colloids: Fundamentals and Applications. *Chem Rev*. 8;117(5):3990-4103, (2017).